The European Medicines Agency (EMA) has accepted the diabetes drug sotagliflozin for review as a therapy for adults with type 1 diabetes. Sotagliflozin, developed by Sanofi and Lexicon Pharmaceuticals, is an investigational twin SGLT1 and SGLT2 inhibitor designed for use in...